Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States

Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes

(2014) A.B. Hauber et al.   VALUE IN HEALTH

Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 μg

(2013) Maria Malmenäs et al.   CLINICAL THERAPEUTICS

Predictors of medication adherence in patients with type 2 diabetes mellitus

(2013) Suellen M. Curkendall et al.   CURRENT MEDICAL RESEARCH AND OPINION

AACE Comprehensive Diabetes Management Algorithm 2013 Endocrine Practice

(2013) Héctor Tamez-Pérez et al.   Endocrine Practice

Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes

(2013) A. Brett Hauber et al.   Patient Preference and Adherence

Standards of Medical Care in Diabetes--2013

(2012)   DIABETES CARE

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis

(2012) Elise M. Pelletier et al.   JOURNAL OF MEDICAL ECONOMICS

A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes

(2011) Carl Asche et al.   CLINICAL THERAPEUTICS

Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes

(2011) Lihua Zhang et al.   JOURNAL OF MEDICAL ECONOMICS

Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study

(2009) Connie M Trinacty et al.   BMC HEALTH SERVICES RESEARCH

Good and poor adherence: optimal cut-point for adherence measures using administrative claims data

(2009) Sudeep Karve et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature

(2009) Maribel Salas et al.   VALUE IN HEALTH

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET